Inactive Instrument

Other languages Cempra Inc Nasdaq

Equities

US15130J1097

Other languages

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Venatorx Pharmaceuticals and Melinta Therapeutics Provide Update on Status of U.S. New Drug Application for Cefepime-Taniborbactam	Feb. 23
New England Journal of Medicine Publishes Positive Results of Cefepime-Taniborbactam from Phase 3 CERTAIN-1 Study of Patients with Complicated Urinary Tract Infection	Feb. 20
Melinta Therapeutics, Llc and Cidara Therapeutics, Inc. Announce Publication of Pooled Data from Phase 3 Pivotal Restore Trial & Phase 2 Strategic Trial of Rezafungin for Injection in the Lancet Id	Dec. 05
Melinta Therapeutics Announces Expanded Reimbursement and Access for REZZAYO (Rezafungin for Injection)	23-10-02
Melinta Therapeutics Partners with BARDA to Advance Two FDA-Approved Antibiotics for Use in Pediatric Patients, and for Use Against Biothreat Pathogens	23-07-10
Cidara Therapeutics and Melinta Therapeutics Announce FDA Approval of REZZAYO (Rezafungin for Injection) for the Treatment of Candidemia and Invasive Candidiasis	23-03-22
Cidara Therapeutics and Melinta Therapeutics Announce FDA Advisory Committee Recommends Approval of Rezafungin for the Treatment of Candidemia and Invasive Candidiasis	23-01-25
Cidara Therapeutics, Inc. and Melinta Therapeutics, LLC Announce Publication of Data from the Global Phase 3 Pivotal ReSTORE Trial of Rezafungin for the Treatment of Candidemia and Invasive Candidiasis in The Lancet	22-11-28
Melinta Therapeutics, Inc. Acquires U.S. Rights to TOPROL-XL® (Metoprolol Succinate) from New American Therapeutics, Inc	22-04-06
Melinta Therapeutics, Inc. Provides Sales Guidance for the Second Quarter of 2019	19-07-16
Melinta Therapeutics, Inc. Reaffirms Sales Guidance for Full Year 2018	18-12-19
Melinta Therapeutics, Inc. Reports Consolidated Earnings Results for the Second Quarter Ended June 30, 2018; Provides Sales Guidance for the Second Half of 2018	18-08-07
Melinta Therapeutics, Inc. Reports Unaudited Consolidated Earnings Results for the First Quarter Ended March 31, 2018; Provides Sales Guidance for the Year of 2018	18-05-08

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Discover our Free Content to Help You Better Understand the Stock Market.

100% Free Registration

fermer